BETWEEN 400 and 500 jobs will be created following the announcement by Pfizer of a €1.2 billion investment at its Grange Castle site in Dublin.
It will bring the total number of Pfizer employees in Ireland to approximately 5,500.
The announcement follows a €40 million investment in the site last year when it was brought onto the global Pfizer Covid-19 manufacturing network.
The investment, which is Pfizer’s biggest expansion investment to date in Ireland, will see a new facility built on the site and will double the capacity for biological drug substance manufacturing at the facility.
"We are very pleased about today's announcement, as it significantly strengthens our operations in Ireland, where we have three high-performing and strategic manufacturing sites," said Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer.
"Grange Castle has played a critical role in our global Covid-19 vaccine network, and this investment for non-Covid licensed and pipeline products, will help to further expand the site’s broad and robust capabilities."
The investment and the roles being created will significantly expand manufacturing and laboratory capacity and add new technologies.
The project is currently in preliminary design phase with construction expected to commence onsite in 2024 and the new facility due for completion in 2027.